Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2009

Eden Biodesign to Manufacture Wound Healing Compound for Omnio

  • Swedish company Omnio Healer selected Eden Biodesign to carry out process development and cGMP mammalian cell manufacture of its lead recombinant protein candidate, which is in development for the treatment of chronic eardrum wounds. The candidate is currently in late preclinical development and is expected to enter the clinic during late 2010.

    One of Karolinska Development’s portfolio companies, Omnio Healer was established in 2006 to exploit the proinflammatory properties of the anticoagulation system for applications in wound healing and anti-infectives.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »